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ABSTRACT
Apolipoprotein C1 (ApoC1) is a component of
multiple lipoproteins where it performs a
variety of roles in lipid metabolism and
transport. ApoC1 exists as both full-length and
truncated isoforms. Truncation of ApoC1 has
been postulated to result from the action of
dipeptidyl peptidase-4 (DPP-4), the target of a
new class of diabetes drugs that includes
sitagliptin phosphate. In this study, we sought
to determine if oral administration of sitagliptin
altered the proportion of ApoC1 isoforms
circulating in humans. Results indicated a
dramatic change in ApoC1 truncation,
consistent with a high level of DPP-4
inhibition by sitagliptin.
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Keywords: Apolipoprotein C1; Mass
spectrometry; Sitagliptin
INTRODUCTION
Apolipoprotein C1 (ApoC1) has a variety of
roles in lipid metabolism and transport. It is
involved in maintaining and stabilizing high-
density lipoprotein (HDL) structure [1], lipase
enzyme regulation [1–3], and inhibition of very
low-density lipoprotein (VLDL) binding to both
the low-density lipoprotein (LDL) receptor and
the LDL receptor-related protein [4, 5]. It also
inhibits cholesterol ester transferase, which
shuttles cholesterol esters and triglycerides
between lipoproteins [6]. The overall effects of
ApoC1 activity are complex and poorly
understood. Overexpression of human ApoC1
in mice produces hyperlipidemia [2, 7],
suggesting that it increases serum lipid levels.
However, in the same mouse models,
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overexpression also protects against diabetes
and obesity. In humans, polymorphisms in
the ApoC1 promoter have been linked to
decreased ApoC1 expression as well as a
hereditary hyperlipidemia syndrome (familial
dysbetalipoproteinemia), cardiovascular
disease, and Alzheimer’s disease [8–12].
ApoC1 exists in vivo as a full-length as well
as in a truncated (ApoC10) isoform, lacking the
two N-terminal amino acids, threonine and
proline. While the ratio of full-length to
truncated protein (ApoC1/ApoC10) has been
shown to differ between individuals, it
remains highly stable within a given
individual over time [13]. The function of full-
length versus truncated protein as well as the
significance of the ratio between the two has yet
to be elucidated [14]. However, biophysical
analysis revealed maximum flexibility and
availability of the amino terminus, making
this site a candidate for protein–protein
interactions [15].
The first-known structural polymorphism of
ApoC1 was recently identified [16]. The
polymorphism, a threonine to serine
substitution at position 45 (T45S) found only
in individuals with American Indian or Mexican
ancestry, resulted in increased levels of
truncated protein and decreased levels of total
ApoC1. The initial study found that the
mutation was associated with increased
distribution to VLDL and a higher body mass
index (BMI). A later study of the Oji-Cree
community in Canada found that the presence
of the polymorphism was associated with
decreased plasma leptin and decreased body
fat [17]. While both reports showed a
physiological effect, they appeared
contradictory. However, the two studies were
of dissimilar subjects, with average age and BMI
of 44 ± 10 years and 29 ± 6 kg/m [18] vs.
25 ± 12 years and 25 ± 5 kg/m [17]. The
polymorphism of the promotor region is
associated with decreased plasma ApoC1 [11]
and with increased Alzheimer’s disease [19].
The enzyme responsible for cleavage of full-
length ApoC1 to its truncated isoform has not
been definitively identified, but has been
suggested to be dipeptidyl peptidase-4 (DPP-4),
a widely distributed serine protease with many
known substrates, including cytokines,
chemokines, growth factors, and
neuropeptides [20]. While this enzyme prefers
cleavage of amino terminal NH2-X-Pro with
optimum cleavage of NH2-Ala-Pro [14] it also
cleaves a large number of other sequences [21,
22] in an apparent protein-dependent manner.
Human ApoC1 contains NH2-Thr-Pro, a suitable
substrate for DPP-4 [21]. In vitro assays have
shown that DPP-4 is capable of cleaving both
the wild-type (T45) and variant (S45) ApoC1,
but that S45 ApoC1 is cleaved more readily,
which is consistent with the higher proportion
of cleaved protein found in individuals with the
polymorphism [16].
Among the many known DPP-4 substrates is
the gastrointestinal hormone, glucagon-like
peptide-1 (GLP-1). GLP-1 acts to increase
insulin secretion, decrease glucagon
production, and slow gastric emptying
following meals, but becomes inactivated by
cleavage with DPP-4 [20, 23]. For this reason,
DPP-4 has become a target for management of
type 2 diabetes. The drug sitagliptin phosphate
is an FDA-approved DPP-4 inhibitor shown to
lower mean blood glucose levels in diabetics by
augmenting GLP-1 levels [24]. Given the
extensive correlation of ApoC1 to disease and
the unexplained presence of two isoforms of the
protein, it is of interest to determine the effect
of sitagliptin on ApoC1 truncation.
This study reports the results of healthy non-
diabetics who were treated with sitagliptin to
compare ApoC1/ApoC10 ratios before and after
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treatment. A significant decrease in truncation
followed treatment, thus providing evidence
that DPP-4 is responsible for cleavage of ApoC1
in humans in vivo.
METHODS
Five healthy volunteers (2F/3 M, age 31.2 ? 8.6,
BMI 23.2 ? 3.1) received 3-day administration
of sitagliptin (100 mg/day). Blood was drawn
into citrate anticoagulant at baseline and
3 days. Mouse and dog plasmas were
purchased from Innovative Research, Novi, MI,
USA. The ratio of full-length to truncated
ApoC1 was determined by matrix-assisted laser
desorption ionization-time of flight (MALDI-
TOF) mass spectrometry as described elsewhere
[25] before and after drug administration.
Plasma ApoC1 concentrations were
determined with a commercial ELISA kit
(Abcam, Cambridge, MA). Data were analyzed
using Prism v5.0c (GraphPad Software, La Jolla,
CA). Statistical analyses were performed using
the Wilcoxon matched pairs signed pairs test.
This study was approved by the Institutional
Review Board of the University of Minnesota.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation at the
University of Minnesota and with the Helsinki
Declaration of 1975, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
RESULTS
The method used in this study has at least two
unique properties. First is that carefully
controlled reverse phase extraction of diluted
plasma with analysis by MALDI-TOF mass
spectrometry results in a small number of
intense peaks. The second is that the ratios of
protein isoforms found the spectrum are
extremely reproducible. The ratio of full-
length to truncated ApoC1 is an example
(Fig. 1). The mass difference in these peaks
(m/z = 6632 - 6434 = 198 amu) corresponds to
loss of Thr-Pro, the expected cleavage of the
amino terminal dipeptide. There are no other
known modifications that are consistent with
this mass change. This isoform ratio was
measured before and after sitagliptin
administration (Fig. 1). An average 2.5 ± 0.28-
fold increase in this ratio was observed (before
average = 2.05 ? 0.22, range 1.76–2.2; after
average = 5.1 ? 0.9, range 3.96–6.25),
corresponding to an average 50% decline of
the truncated ApoC1 (33% to 17%). Prior
studies of plasma drawn from healthy
individuals at baseline and again at 3 years
showed stable ratios of full-length to truncated
ApoC1 with an average of 0.96 ± 0.07 (ratio at
Fig. 1 Effect of sitagliptin treatment on isoforms of
ApoC1. MALDI-TOF proﬁle of ApoC1 from subject 1
prior to (a) and after (b) treatment with sitagliptin. The
peak at m/z = 6632 corresponds to full-length ApoC1
while the peak at 6434 is truncated ApoC1. ApoC1
Apolipoprotein C1, MALDI-TOF matrix-assisted laser
desorption ionization-time of ﬂight
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3 year/ratio at baseline [25]). Thus, the change
observed following sitagliptin was exceptional,
corresponding to 35 standard deviations greater
than normal variation. This also occurred in
only 3 days.
Although truncation may serve several
purposes, one may be protein turnover. For
example, lower ApoC1 in persons with the T45S
variant would be consistent with enhanced
removal of the truncated protein from the
circulation. If correct, inhibition of truncation
due to sitagliptin should result in decreased
turnover and a corresponding increase of total
ApoC1. However, plasma ApoC1 concentrations
were unchanged after sitaglipin administration
as determined with a commercial ELISA kit
(Abcam, Cambridge, MA) (average ratio for
each individual before/after drug = 0.99 ? 0.05,
range among subjects = 36–53 lg ApoC1/mL).
Additional evidence for ApoC1 cleavage by
DPP-4 was obtained by species comparisons.
Mouse ApoC1 contains the putative optimum
DPP-4 substrate sequence of NH2-Ala-Pro. Earlier
studies by electrospray ionization mass
spectrometry reported a preponderance of
truncated ApoC1 in the mouse [26]. MALDI-TOF
profile analysis by the method used for human
ApoC1 confirmed this finding with a major peak at
m/z= 6825, corresponding to truncated mouse
ApoC1 and only trace levels of a component
corresponding to the full-length form at m/
z= 6994 (Fig. 2a). In contrast, canine ApoC1
contains the amino terminal sequence of NH2-
Ala-Gly, a poorer substrate for DPP-4 [21]. Earlier
studies by electrospray mass spectrometry reported
a single isoform of canine ApoC1 at m/z= 7042
[27], corresponding to the full-length protein. In
agreement, MALDI-TOF mass spectrometry by the
methodoutlined inthis studyshowedasinglepeak
at the m/z corresponding to full-length canine
ApoC1 (Fig. 2b).
DISCUSSION
Overall, this study supported the conclusion
that truncation of ApoC1 arises from the action
Fig. 2 ApoC1 andApoC10 peak intensities inmouse and dog
plasmas. aMALDI-TOF proﬁle showing an expanded view of
the ApoC1 region from a representativemouse plasma sample.
b MALDI-TOF proﬁle showing an expanded view of the
ApoC1 region from a representative dog plasma sample.
ApoC1 Apolipoprotein C1, ApoC10 truncated isoform of
Apolipoprotein C1, MALDI-TOF matrix-assisted laser des-
orption ionization-time of ﬂight
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of DPP-4, as hypothesized. This was indicated
by a dramatic decline of truncated ApoC1
following sitagliptin administration in each of
the five subjects. Extensive prior studies found
no basis for this large change among the
healthy population [25]. This interpretation
was based on an assumed specificity of
sitagliptin for DPP-4. Thus, a more precise
conclusion was that sitagliptin inhibited
truncation of ApoC1. Consequently, change in
the ratio of ApoC1 isoforms is an unappreciated
side effect of DPP-4 inhibitors.
The decline of truncated protein was
consistent with the target level for DPP-4
inhibition by sitagliptin. Given a mean
residence time for ApoC1 of 3.7 ? 0.3 days
[28], or a half-life of 2.56 days, full inhibition
of DPP-4 should result in a 50% decline of
truncated protein in approximately 2.56 days.
Assuming first-order kinetics with respect to
ApoC1 and DPP-4, fifty percent decline in
3.0 days corresponded to approximately 85%
inhibition of DPP-4, very nearly the target for
drug administration [29].
Although the role of truncation is not
known, several suggestions indicate that
further study is warranted. It is also possible
that measuring the truncation level of ApoC1
could be used to monitor drug efficacy in
individual patients, similar to how glycation of
hemoglobin (hemoglobin A1c) is used to
monitor blood glucose levels over time in
diabetic patients.
CONCLUSION
In this study we sought to determine if oral
administration of sitagliptin altered the
proportion of ApoC1 isoforms circulating in
humans. Results indicated a dramatic change in
ApoC1 truncation, consistent with a high level
of DPP-4 inhibition by sitagliptin.
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